A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma

INTRODUCTION: The current standard of care for newly diagnosed glioblastoma (GBM) is maximum surgical resection followed by concurrent treatment with temozolomide (TMZ) and radiotherapy (RT) and then six to twelve cycles of maintenance TMZ. RRx-001, an NLRP3 inhibitor and nitric oxide (NO) donor wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Fine, Howard, Reid, Tony, Caroen, Scott, Oronsky, Bryan, Abrouk, Nacer, Butowski, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277641/
https://www.ncbi.nlm.nih.gov/pubmed/37342189
http://dx.doi.org/10.3389/fonc.2023.1176448

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277641/
https://www.ncbi.nlm.nih.gov/pubmed/37342189
http://dx.doi.org/10.3389/fonc.2023.1176448

Ejemplares similares